Each episode of AJP Audio brings you an in-depth look at one of the articles featured in that month’s issue of The American Journal of Psychiatry, the official journal of the American Psychiatric Association. Wide-ranging interviews with article authors cover the background, rationale, main findings, and future implications of the research. This podcast is subject to the Terms of Use at ww.psychiatry.org. The views and opinions expressed in this podcast are those of the individual speakers only and do not necessarily represent the views of the American Psychiatric Association, its officers, trustees, or members. The content of this podcast is provided for general informational purposes only and is not intended as, and shall not be understood or construed as, medical or any other type of professional advice nor does it represent any statement of the standard of care. We strongly recommend that any listener follow the advice of physicians directly involved in their care and contact their local emergency response number for any medical emergency. The information within this podcast is provided as-is and is not guaranteed to be correct, complete, or accurate.
https://ajp.psychiatryonline.org/audio
January 2022: Cannabis Use and the Endocannabinoid System
In this month’s AJP Audio, Dr Margert Haney (Director of the Cannabis Research Laboratory at Columbia Psychiatry) discusses her new review from the January issue of the American Journal of Psychiatry, “Cannabis Use and the Endocannabinoid System: A Clinical Perspective,” and the questions around the legal status of cannabis research. Afterward, Dr. Ned Kalin, Editor-in-Chief of the Journal discusses the January 2022 issue of AJP.
- Haney interview: How does cannabis interact with our brains? [00:30]
- CBD and how it’s different [01:26]
- Impact of state legalization of cannabis on research [02:08]
- Federal attitudes towards cannabis legalization [03:43]
- A single source of cannabis for research [04:57]
- Limitations on research and an expanding, unexamined market [06:11]
- Marketing of other cannabinoids [06:38]
- Consequences of cannabis legalization [08:06]
- Cannabis use disorder [08:36]
- What happens with daily cannabis use – and abrupt cessation? [09:27]
- What happens to your endocannabinoid system with daily use? [10:36]
- A proliferating market and constrained research [11:56]
- Patients foregoing FDA-approved medication in favor of cannabis products [12:14]
- There’s a reason we have randomized controlled clinical trials with placebo [12:37]
- Changes in cannabis use and abuse [13:31]
- Public perception of cannabis use disorder [14:26]
- What’s next for cannabis research? [15:20]
- Loosening of cannabis sources [16:03]
- No US source for CBD to study [16:36]
- Future changes in the status quo? [17:24]
- Importance of the endogenous cannabinoid system [18:41]
- Potential consequences during vulnerable times in brain development: in utero and adolescence [19:08]
- Marketing cannabis to pregnant women [19:45]
- Kalin interview [20:30]
- Alcohol and cannabis use disorders [20:39]
- Haney [21:43]
- Browne et al. [22:34]
- Livne et al. [23:31]
- Mellentin et al. [25:38]
- Mallard et al. [27:39]
- In sum [28:30]
Be sure to let your colleagues know about the podcast, and please rate and review it on Apple Podcasts, Google Podcasts, Stitcher, Spotify, or wherever you listen to it.
Subscribe to the podcast here.
Listen to other podcasts produced by the American Psychiatric Association.
Browse articles online.
How authors may submit their work.
Follow the journals of APA Publishing on Twitter.
E-mail us at ajp@psych.org